Could Glutamate Be a New Key to Migraine Treatment
Information presented at the 61st Annual Meeting of the American Academy of Neurology (April, 2009) indicates that glutamate receptors may play a role in Migraine treatment.
Trial Phase IIa data showed Addex Pharmaceuticals' ADX10059, an investigational glutamate receptor inhibitor, could prove helpful for Migraine prevention. Other early trials have shown ADX1005 to be an effective abortive treatment for acute migraine attacks.
Glutamate is a neurotransmitter, a chemical occurring naturally in the brain that transmits messages from one nerve cell to another.
A theory under investigation is that since glutamate receptors are found in regions of the brain involved in Migraine, inhibiting transmission through glutamate receptors could lead to Migraine treatments.
Read more in Glutamate: A New Key to Migraine Treatment?